– USA, CA – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the appointment of Michel Vounatsos to its board of directors.
“Michel brings a wealth of experience in the commercial development of late-stage therapeutics. His governance and strategy will benefit our Phase 3 approved cancer asset and commercially approved pathogen vaccine asset,” said CEO, Dr. Hans S. Keirstead.
About Michel Vounatsos
Michel Vounatsos is a career healthcare executive and former CEO of Biogen. Before joining Biogen, Michel had a 20-year career at Merck where he held commercial leadership positions across Europe. He also held management positions at Ciba-Geigy, a pharmaceutical company.
He holds a CSCT certificate in Medicine from the Université Victor Segalen, Bordeaux II, France, and an MBA from the HEC School of Management in Paris.
About AIVITA Biomedical
Founded in 2016 by pioneers in the cell therapy industry, AIVITA Biomedical, Inc. utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient, and economical manufacturing systems that support its therapeutic pipeline. Our cancer immunotherapy targets the seed of all cancers, tumor-initiating cells, with a unique pan-antigenic approach that targets all neoantigens specific to the patient’s cancer. Our patient-specific cancer treatments have shown great promise including eradicating tumors, without harmful side effects in melanoma, and renal cell cancer, and prolonging progression-free survival in glioblastoma. Our Vaccine Enabling Kit for infectious diseases is targeted to emerging nations enabling point-of-care vaccine production in minimally equipped facilities by minimally trained third-party technicians.
SOURCE: https://www.aivitabiomedical.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
